At the time of writing, Beam Therapeutics Inc [BEAM] stock is trading at $17.00, up 2.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The BEAM shares have gain 16.20% over the last week, with a monthly amount drifted -28.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on March 28, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $42 for it. Previously, Scotiabank upgraded its rating to Sector Outperform on March 10, 2025, and kept the price target unchanged to $40. On January 29, 2025, upgrade upgraded it’s rating to Overweight. Leerink Partners upgraded its rating to a Outperform and increased its price target to $39 on November 06, 2024. Scotiabank initiated its recommendation with a Sector Outperform. H.C. Wainwright started tracking with a Buy rating for this stock on July 23, 2024, and assigned it a price target of $80. In a note dated January 29, 2024, JP Morgan upgraded an Overweight rating on this stock and boosted its target price from $38 to $40.
For the past year, the stock price of Beam Therapeutics Inc fluctuated between $13.52 and $35.25. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $17.00 at the most recent close of the market. An investor can expect a potential return of 132.35% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
According to Beam Therapeutics Inc [NASDAQ:BEAM], the company’s sales were 63.52M for trailing twelve months, which represents an -90.49% plunge. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -6.54%, Pretax Profit Margin comes in at -5.93%, and Net Profit Margin reading is -5.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.46 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.59 points at the first support level, and at 16.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.30, and for the 2nd resistance point, it is at 17.61.
Ratios To Look Out For
It is important to note that Beam Therapeutics Inc [NASDAQ:BEAM] has a current ratio of 4.82. On the other hand, the Quick Ratio is 4.82, and the Cash Ratio is 1.55. Considering the valuation of this stock, the price to sales ratio is 26.72, the price to book ratio is 1.94.
Transactions by insiders
Recent insider trading involved Bellon Christine, Chief Legal Officer, that happened on Apr 01 ’25 when 5674.0 shares were sold. CEO, Evans John M. completed a deal on Apr 01 ’25 to sell 30663.0 shares. Meanwhile, President Ciaramella Giuseppe sold 7434.0 shares on Apr 01 ’25.
